Your search for ‘Smart & Biggar’ returned 2,497 results

The Federal Court of Appeal found that the application judge made no reviewable error in finding that the TPD's decision was not improperly motivated, and dismissed the appeal.

Health Canada announced it will move forward with Phase III of its prescription drug product transparency initiatives.

Justice Locke also held that AstraZeneca was entitled to a declaration of infringement and ordered the quantification of AstraZeneca's damages or Apotex's profits.

As we previously reported, Canada will be significantly changing its trademark law.

The Patented Medicine Prices Review Board (PMPRB) released its March 2018 NEWSletter (the first NEWSletter since July 2017). Highlights include:

Eli Lilly seeks leave in olanzapine section 8 damages action.

As previously reported, the Federal Court of Appeal (FCA) dismissed Teva's appeal on the quantification of damages from infringement of Janssen's patent for levofloxacin (LEVAQUIN).

On February 2, the FCA allowed Apotex's appeal of a $61 million award disgorging Apotex's profits for its generic perindopril (COVERSYL).

Food and Drugs Act amendments: Bill C-97, tabled in April, proposed amendments to the Food and Drugs Act, including a new framework for "Advanced Therapeutic Products"

Canada's federal government and common law provinces lack a general 'right of publicity' protecting personality rights as property. This article examines the limited statutory provisions covering personality rights in Canada, with Quebec as a notable exception under civil law jurisdiction.

As previously reported, the Federal Court of Appeal (FCA) dismissed Apotex's appeal of a judicial review decision of the Therapeutic Products Directorate (TPD) ...

While the Court of Appeal held that the Federal Court erred in its identification of the inventive concept, it upheld the finding that the patent was obvious.

Earlier this year, the Canadian Patent Office announced that it will increase its official fees on January 1, 2024, in some cases by as much as 36%.

The appellants argued that Apo-Lansoprazole could not and would not have received regulatory approval in April 2007 and Apotex was not entitled to damages.

On November 30, 2018, Global Affairs Canada issued a news release announcing the signing of the Canada-United States-Mexico Agreement (CUSMA or USMCA) ...

On January 30, 2018, the Government of Canada posted the Comprehensive and Progressive Partnership for Trans-Pacific Partnership (CPTPP) - Backgrounder.

In view of the COVID-19 outbreak, the Canadian Intellectual Property Office (CIPO) has announced that patent, trademark,...

The Economic Action Plan 2014 Act, No. 1, which includes significant amendments to the Trade-marks Act, received Royal Assent on June 19, 2014.